Retraction notice to "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial" [International Journal of Antimicrobial Agents 56 (2020), 105949].
作者信息
Gautret Philippe, Lagier Jean-Christophe, Parola Philippe, Hoang Van Thuan, Meddeb Line, Mailhe Morgane, Doudier Barbara, Courjon Johan, Giordanengo Valérie, Vieira Vera Esteves, Dupont Hervé Tissot, Honoré Stéphane, Colson Philippe, Chabrière Eric, La Scola Bernard, Rolain Jean-Marc, Brouqui Philippe, Raoult Didier
机构信息
IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, AP-HM, SSA, VITROME, Marseille, France.
IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, APHM, MEPHI, Marseille, France.
出版信息
Int J Antimicrob Agents. 2025 Jan;65(1):107416. doi: 10.1016/j.ijantimicag.2024.107416. Epub 2024 Dec 26.
Abstract
摘要
相似文献
1
Retraction notice to "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial" [International Journal of Antimicrobial Agents 56 (2020), 105949].撤稿通知：“羟氯喹和阿奇霉素治疗COVID-19：一项开放标签非随机临床试验的结果”[《国际抗微生物药物杂志》56(2020)，105949]
Int J Antimicrob Agents. 2025 Jan;65(1):107416. doi: 10.1016/j.ijantimicag.2024.107416. Epub 2024 Dec 26.
2
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.羟氯喹和阿奇霉素治疗 COVID-19：一项开放标签非随机临床试验的结果。
Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20.
3
Doxycycline vs Hydroxychloroquine + Azithromycin in the Management of COVID-19 Patients: An Open-Label Randomized Clinical Trial in Sub-Saharan Africa (DOXYCOV).多西环素与羟氯喹啉联合阿奇霉素治疗新冠肺炎患者的疗效对比：撒哈拉以南非洲地区的一项开放标签随机临床试验（DOXYCOV）
Cureus. 2023 Sep 20;15(9):e45619. doi: 10.7759/cureus.45619. eCollection 2023 Sep.
4
Focus on clinical outcomes of "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial".关注“羟氯喹和阿奇霉素治疗新型冠状病毒肺炎：一项开放标签非随机临床试验的结果”的临床结局。
Int J Antimicrob Agents. 2021 Jan;57(1):106175. doi: 10.1016/j.ijantimicag.2020.106175.
5
Letter to the editor about "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial".致编辑的信：关于“羟氯喹和阿奇霉素作为治疗新型冠状病毒肺炎的药物：一项开放标签非随机临床试验的结果”
Int J Antimicrob Agents. 2021 Jan;57(1):106171. doi: 10.1016/j.ijantimicag.2020.106171.
6
Referring to the study: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial.参考研究：《羟氯喹和阿奇霉素治疗新型冠状病毒肺炎：一项开放标签非随机临床试验的结果》
Int J Antimicrob Agents. 2021 Jan;57(1):106176. doi: 10.1016/j.ijantimicag.2020.106176.
7
Pakistan Randomized and Observational Trial to Evaluate Coronavirus Treatment (PROTECT) of Hydroxychloroquine, Oseltamivir and Azithromycin to treat newly diagnosed patients with COVID-19 infection who have no comorbidities like diabetes mellitus: A structured summary of a study protocol for a randomized controlled trial.巴基斯坦评估羟氯喹、奥司他韦和阿奇霉素治疗新冠病毒感染的随机和观察性试验（PROTECT）：针对无糖尿病等合并症的新发 COVID-19 感染患者的治疗：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Aug 8;21(1):702. doi: 10.1186/s13063-020-04616-4.
8
Direct antivirals working against the novel coronavirus: azithromycin (DAWn-AZITHRO), a randomized, multicenter, open-label, adaptive, proof-of-concept clinical trial of new antivirals working against SARS-CoV-2-azithromycin trial.直接针对新型冠状病毒的抗病毒药物：阿奇霉素（DAWn-AZITHRO），一项针对新型冠状病毒的新型抗病毒药物的随机、多中心、开放标签、适应性、概念验证临床试验-阿奇霉素试验。
Trials. 2021 Feb 9;22(1):126. doi: 10.1186/s13063-021-05033-x.
9
Review of: "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Gautret et al 2010, DOI:10.1016/j.ijantimicag.2020.105949.《羟氯喹啉和阿奇霉素治疗新型冠状病毒肺炎：一项开放标签非随机临床试验的结果》综述 Gautret等人，2010年，DOI:10.1016/j.ijantimicag.2020.105949
Int J Antimicrob Agents. 2020 Jul;56(1):106063. doi: 10.1016/j.ijantimicag.2020.106063. Epub 2020 Jul 13.
10
Efficacy of Ivermectin, Chloroquine/Hydroxychloroquine, and Azithromycin in Managing COVID-19: A Systematic Review of Phase III Clinical Trials.伊维菌素、氯喹/羟氯喹及阿奇霉素治疗新冠肺炎的疗效：III期临床试验的系统评价
Biomedicines. 2024 Sep 27;12(10):2206. doi: 10.3390/biomedicines12102206.
引用本文的文献
1
COVID-19 and a Tale of Three Drugs: To Repurpose, or Not to Repurpose-That Was the Question.新冠疫情与三种药物的故事：是否进行药物再利用——这就是问题所在。
Viruses. 2025 Jun 23;17(7):881. doi: 10.3390/v17070881.
2
Coronavirus in Continuous Flux: From SARS-CoV to SARS-CoV-2.不断演变的冠状病毒：从严重急性呼吸综合征冠状病毒到严重急性呼吸综合征冠状病毒2
Adv Sci (Weinh). 2020 Aug 16;7(20):2001474. doi: 10.1002/advs.202001474. eCollection 2020 Oct.
Zotero 插件